Breast Cancer | Current Treatment | EU5 | 2016

Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. HER2-targeting therapy is the cornerstone of treatment regardless of HR status. This analysis provides insight on the current use of approved therapies for HER2-positive breast cancer in the EU5 and on factors driving physicians’ prescribing decisions.

Login to access report

Back to all Market Assessment reports